Private Advisor Group LLC Acquires 2,255 Shares of Insulet Co. (NASDAQ:PODD)

Private Advisor Group LLC lifted its holdings in Insulet Co. (NASDAQ:PODD) by 30.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 9,642 shares of the medical instruments supplier’s stock after buying an additional 2,255 shares during the quarter. Private Advisor Group LLC’s holdings in Insulet were worth $2,517,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Integrated Wealth Concepts LLC boosted its stake in Insulet by 1.7% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock worth $596,000 after purchasing an additional 42 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Insulet by 1.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock worth $1,146,000 after buying an additional 43 shares in the last quarter. Glenmede Trust Co. NA boosted its position in shares of Insulet by 2.3% during the third quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock worth $484,000 after acquiring an additional 47 shares during the last quarter. Graypoint LLC grew its stake in Insulet by 5.3% during the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock valued at $243,000 after acquiring an additional 47 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB increased its holdings in Insulet by 9.6% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier’s stock valued at $140,000 after acquiring an additional 47 shares during the last quarter.

Insulet Stock Up 0.2 %

Shares of NASDAQ PODD opened at $283.48 on Tuesday. The company has a market cap of $19.88 billion, a P/E ratio of 48.96, a PEG ratio of 3.62 and a beta of 1.23. The firm has a 50-day simple moving average of $273.33 and a two-hundred day simple moving average of $248.46. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. Research analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Piper Sandler increased their price objective on shares of Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a report on Friday. BTIG Research raised their price target on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday, November 8th. Barclays upped their price objective on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Sanford C. Bernstein assumed coverage on shares of Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. Finally, Citigroup upped their price target on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research note on Friday. Three investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $289.06.

Insider Activity at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by company insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.